Logo Image
Opinion|Videos|March 6, 2025

New Intravesical Delivery Systems and TAR-200 in NMIBC

Experts review different treatment delivery options available for the management of non–muscle-invasive bladder cancer (NMIBC), discuss the exciting developments in NMIBC with several delivery systems and agents under investigation, and provide information about TAR-200, a targeted release system utilizing continuous intravesical release of gemcitabine, including how TAR-200 is installed within the bladder.

Episodes in this series

Video content above is prompted by the following:

  • Please review different treatment delivery options available for management of NMIBC.
  • It is an exciting time for NMIBC, as several delivery systems and agents are currently under investigation for treatment of NMIBC.
  • To start with, please share information about TAR-200, a targeted release system that utilizes continuous intravesical release of gemcitabine.
  • Describe how TAR-200 is installed within the bladder.

Related Content

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies
Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more